West Pharmaceutical Services, Inc. (WST) Stock Analysis
West Pharma is becoming the “indispensable bottleneck” of the injectable super‑cycle—monetizing biologics, GLP‑1 scale, and Annex 1-driven forced upgrades through high‑value components and higher‑margin drug handling.
Overview
West Pharmaceutical Services (WST) is emerging as a critical infrastructure provider for the injectable medicine ecosystem as the industry pivots toward biologics and high-volume GLP‑1 therapies. After working through post-pandemic destocking, FY2025 showed a clear recovery: net sales rose to $3.074B (+6.3%), adjusted EPS grew 8%, operating cash flow increased to ~$755M (+15.5%), and free cash flow surged to ~$469M (+69.6%), enabling reinvestment and shareholder returns. Q1 2026 was the key inflection, with net sales of $844.9M (+21% reported, +15.3% organic) and adjusted EPS of $2.13 (+46.9%), alongside meaningful margin expansion from HVP mix and pricing. Management raised 2026 guidance to $3.295–$3.350B revenue and $8.40–$8.75 adjusted EPS, reflecting confidence that demand across biologics, GLP‑1, and Annex 1-driven HVP conversion is durable. Strategically, the rebrand to “West Vantage” signals a shift toward higher-margin drug handling and integrated solutions, expanding value capture beyond components alone.